Cytek Biosciences (CTKB) UBS Genomic Medicine Summit summary

Technology innovation and platform development

• Companies are advancing spatial biology, proteomics, and imaging platforms, each targeting unique aspects of cellular analysis and diagnostics.

• New platforms like CellScape and CosMx are being positioned for both research and future clinical use, with a focus on scalability and high-plex capabilities.

• AI-driven image analysis and deep learning are increasingly critical for handling large, complex datasets generated by high-plex and spatial technologies.

• Companies are integrating multiple modalities, such as transcriptomics, proteomics, and epigenomics, to expand the utility of their platforms.

• Emphasis is placed on developing user-friendly, robust, and standardized platforms to facilitate adoption in both research and clinical settings.

Market adoption, challenges, and opportunities

• Spatial biology and related technologies are in the early stages of adoption, with product cycles expected to span 10–15 years or more.

• Adoption curves may accelerate with demonstrated clinical efficacy, as seen in other diagnostic markets.

• Service-based models and leveraging existing installed bases (e.g., Illumina NovaSeq) are seen as ways to accelerate market penetration.

• Ease of use, cost, and automation are key factors for expanding market reach and supporting high-plex applications.

• Global opportunities are being considered, with some platforms designed for cloud-based data processing and low-cost deployment.

Clinical translation and unmet needs

• There is a shift from high-plex, discovery-focused research tools to more streamlined, clinically applicable proteomics platforms.

• Current diagnostic tools for immunotherapy response are limited; new imaging and phenotypic platforms aim to address this gap.

• Trials are underway to validate new platforms' efficacy in predicting therapy response, with results expected in the near future.

• Standardization of data analysis and experiment quality is a major challenge, with AI and automation proposed as solutions.

• Multiplex tools are increasingly necessary for guiding antigen-directed therapies in oncology.